In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...

Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.

Researchers in Gastroenterology evaluated strategies for preventing avoidable colorectal cancers after colonoscopy. In ...

We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...

CervoMed has announced positive results from the extension phase 2b RewinD-LB study of neflamapimod for dementia with Lewy ...

Proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit.

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

Also Read: Weight Loss Drugs Soar While Global Obesity Rates ... In December, in the REDEFINE 1 Phase 3 trial, CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction ...